[Federal Register: January 20, 2006 (Volume 71, Number 13)]
[Notices]
[Page 3307]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20ja06-67]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting.
Name: Clinical Laboratory Improvement Advisory Committee
(CLIAC).
Times and Dates: 8:30 a.m.-5 p.m., February 8, 2006; 8:30 a.m.-3
p.m., February 9, 2006.
Place: Doubletree Hotel (Atlanta/Buckhead), 3342 Peachtree Road
NE., Atlanta, Georgia 30326, Telephone: (404) 231-1234.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary, Department of Health
and Human Services; the Assistant Secretary for Health; and the
Director, CDC, regarding the need for, and the nature of, revisions
to the standards under which clinical laboratories are regulated;
the impact on medical and laboratory practice of proposed revisions
to the standards; and the modification of the standards to
accommodate technological advances.
Matters To Be Discussed: The agenda will include updates from
the Food and Drug Administration, the Centers for Medicare &
Medicaid Services, and CDC; reports on national cytology proficiency
testing status and Coordinating Council on the Clinical Laboratory
Workforce activities addressing laboratory personnel shortages; and
the role of the public health laboratory, including scope of
services, customers, connectivity, and preparedness.
Agenda items are subject to change as priorities dictate.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible. Oral Comments: In general, each
individual or group requesting to make an oral presentation will be
limited to a total time of five minutes (unless otherwise
indicated). Speakers must also submit their comments in writing for
inclusion in the meeting's Summary Report. To assure adequate time
is scheduled for public comments, individuals or groups planning to
make an oral presentation should, when possible, notify the contact
person below at least one week prior to the meeting date. Written
Comments: For individuals or groups unable to attend the meeting,
CLIAC accepts written comments until the date of the meeting (unless
otherwise stated). However, the comments should be received at least
one week prior to the meeting date so that the comments may be made
available to the Committee for their consideration and public
distribution. Written comments, one hard copy with original
signature, should be provided to the contact person below. Written
comments will be included in the meeting(s Summary Report.
Contact Person for Additional Information: Devery Howerton,
Acting Chief, Laboratory Practice Standards Branch, Division Public
Health Partnerships--Laboratory Systems, National Center for Health
Marketing, Coordinating Center for Health Information and Service,
CDC, 4770 Buford Highway NE., Mailstop G-23, Atlanta, Georgia 30341-
3717; telephone (770) 488-8155; fax (770) 488-8279; or via e-mail at
DHowerton@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 06-518 Filed 1-19-06; 8:45 am]
BILLING CODE 4163-18-P